BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

{1} Receives Phase I {2} Grant


2/25/2013 2:13:49 PM

February 26, 2013 (CLEVELAND, OHIO) Clinical stage biotechnology startup Milo Biotechnology has received a $300,000 Phase I SBIR grant from NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The grant, which was awarded under NIAMS’ new Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases program, will enable Milo Biotechnology to study the efficacy of regional follistatin delivery in small and large animals.

“The therapies we are developing to treat muscular dystrophy work to increase muscle strength or decrease the rate of muscle atrophy,” says Milo Biotechnology CEO Al Hawkins. “This award is critical to this stage of Milo’s development, as it will allow us to take the next steps toward effective therapies for systemic muscle wasting.”

Milo Biotechnology’s therapy is based on adeno-associated virus delivery of follistatin, a protein that increases muscle strength and prevents atrophy. Follistatin functions primarily by blocking myostatin, a protein that reduces muscle strength. The company’s lead program for local muscle strengthening is currently in a Phase I/II clinical trial for patients with Becker muscular dystrophy and inclusion body myositis. “Milo Biotechnology’s ultimate goal is to develop a suite of therapeutic candidates that can serve the needs of a variety of patient populations,” Hawkins says.

For more information about Milo Biotechnology or its therapies, visit the company’s recently launched website, www.milobiotechnology.com.

About Milo Biotechnology Milo Biotechnology is an early clinical stage startup company developing therapies to strengthen muscle and improve the lives of patients with neuromuscular diseases. Its lead program, AAV1-FS344, leads to the local expression of follistatin, a myostatin inhibitor. Milo’s core technology was developed at and is exclusively licensed from Nationwide Children’s Hospital in Columbus, Ohio; the company is based in Cleveland, Ohio, and has received funding from JumpStart Inc. and Cuyahoga County North Coast Opportunities Fund. Visit www.milobiotechnology.com for more information.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES